Acepodia, Inc. (TPEX:6976)
Taiwan · Delayed Price · Currency is TWD 12.40
-0.90 (-6.77%)
Sep 8, 2026, 1:00 PM CST
Acepodia Revenue
In the year 2025, Acepodia had annual revenue of 185.00K TWD, down -56.67%.
Revenue
185.00K
Revenue Growth
-56.67%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
7.75B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 185.00K | -242.00K | -56.67% |
| Dec 31, 2024 | 427.00K | -16.17M | -97.43% |
| Dec 31, 2023 | 16.59M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.45B |
| Adimmune | 1.37B |
| Savior Lifetec | 1.12B |
| PharmaEngine | 1.03B |
| Tanvex BioPharma | 657.56M |
| TaiGen Biopharmaceuticals Holdings | 256.46M |
| Polaris Group | 67.95M |
| Locus Cell | 19.40M |